Technical Analysis for MEIP - MEI Pharma, Inc.

Grade Last Price % Change Price Change
grade B 3.11 1.97% 0.06
MEIP closed up 1.97 percent on Friday, May 24, 2019, on 49 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Down
See historical MEIP trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Spinning Top Other 0.00%
MACD Bearish Signal Line Cross Bearish 1.97%
200 DMA Resistance Bearish 2.30%
Fell Below 20 DMA Bearish 2.30%
Fell Below 50 DMA Bearish 2.30%
Expansion Pivot Sell Setup Bearish Swing Setup 2.30%
Slingshot Bullish Bullish Swing Setup 2.30%
Down 3 Days in a Row Weakness 2.30%

Older signals for MEIP ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
MEI Pharma, Inc., a development stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. It develops various lead drug candidates, including ME-143 that has completed Phase I clinical trials in patients with refractory solid tumors; ME-344, an active metabolite of NV-128, which is in Phase I clinical trials in patients with solid refractory tumors; and Pracinostat, an orally histone deacetylase inhibitor that has completed various Phase I clinical trials in patients with hematologic disorders. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited. MEI Pharma, Inc. (NasdaqCM:MEIP) operates independently of Novogen Limited as of December 03, 2012.
Medicine Cancer Clinical Medicine Treatment Of Cancer Virotherapy Seattle Genetics Kite Pharma Hematologic Disorders Refractory Solid Tumors
Is MEIP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.14
52 Week Low 1.82
Average Volume 160,644
200-Day Moving Average 3.2285
50-Day Moving Average 3.1049
20-Day Moving Average 3.115
10-Day Moving Average 3.158
Average True Range 0.1623
ADX 14.21
+DI 18.5498
-DI 20.1665
Chandelier Exit (Long, 3 ATRs ) 2.9231
Chandelier Exit (Short, 3 ATRs ) 3.3169
Upper Bollinger Band 3.3265
Lower Bollinger Band 2.9035
Percent B (%b) 0.49
BandWidth 13.579454
MACD Line 0.0142
MACD Signal Line 0.0182
MACD Histogram -0.004
Fundamentals Value
Market Cap 114.88 Million
Num Shares 36.9 Million
EPS 0.07
Price-to-Earnings (P/E) Ratio 44.43
Price-to-Sales 4.35
Price-to-Book 1.98
PEG Ratio 23.80
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.35
Resistance 3 (R3) 3.34 3.25 3.31
Resistance 2 (R2) 3.25 3.19 3.26 3.30
Resistance 1 (R1) 3.18 3.15 3.22 3.19 3.28
Pivot Point 3.09 3.09 3.11 3.10 3.09
Support 1 (S1) 3.02 3.03 3.06 3.03 2.94
Support 2 (S2) 2.93 2.99 2.94 2.92
Support 3 (S3) 2.86 2.93 2.91
Support 4 (S4) 2.87